Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.
- DOI
- 10.1002/ijc.70265
- Published
- 2026 May 1
- Container
- International journal of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ijc.70265,
title = {Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1\%: KEYNOTE-042 China study.},
author = {Wu YL and Zhang L and Fan Y and Zhou J and Zhang L and Zhou Q and Li W and Hu C and Chen G and Zhang X and Zhou C and Arenas CG and Chen Z and Yu WC and Mok TSK},
year = {2026},
journal = {International journal of cancer},
doi = {10.1002/ijc.70265},
url = {https://doi.org/10.1002/ijc.70265}
}RIS
TY - JOUR TI - Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study. AU - Wu YL AU - Zhang L AU - Fan Y AU - Zhou J AU - Zhang L AU - Zhou Q AU - Li W AU - Hu C AU - Chen G AU - Zhang X AU - Zhou C AU - Arenas CG AU - Chen Z AU - Yu WC AU - Mok TSK PY - 2026 JO - International journal of cancer DO - 10.1002/ijc.70265 UR - https://doi.org/10.1002/ijc.70265 ER -
APA
YL, W., L, Z., Y, F., J, Z., L, Z., Q, Z., W, L., C, H., G, C., X, Z., C, Z., CG, A., Z, C., WC, Y., & TSK, M. (2026). Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study.. International journal of cancer. https://doi.org/10.1002/ijc.70265
Source records
- pubmed · retrieved 2026-09-26T08:51:24.253Z